Prostatic Hyperplasia Clinical Trial
Official title:
A Pivotal, Open-label Trial Assessing the Safety and Efficacy of the 0.5 mg Dutasteride and 0.4 mg Tamsulosin Combination Once Daily for Six Months in Patients With Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90
subjects will be enrolled so that among them at least 57 will complete the 6-month treatment
period and evaluable for analysis.
-Primary objective: To assess the safety of 0.5 mg dutasteride/0.4 mg tamsulosin combination
therapy for six month in BPH patients by monitoring category, frequency and severity of
adverse events encountered during the treatment period.
-Secondary objective: To assess the efficacy of 0.5 mg dutasteride/0.4 mg tamsulosin
combination therapy with regard to symptom improvement in BPH patients by monitoring and
analyzing of changes in IPSS and Qmax after 6 months of treatment.
Visit 0 or Screening Visit (M0) - D0 + 2): Following tasks will be performed: ICF collection, subject code assignment, physical examination (vital signs, demographic data, medical history); checking of inclusion and exclusion criteria: prostate symptom score according to IPSS, laboratory tests (hematology, blood chemistry, electrolytes, total PSA level, free-to-total PSA ratio, Qmax, urinalysis, transrectal prostate ultrasonography (TRUS), 12-lead electrocardiography (ECG), scoring of Sexual Function Questionnaire (SFQ), concomitant medication assessment, IP dispensing. • Visit 1 (Month 1 (M1) - D30 ± 3): Following items will be recorded: treatment compliance, vital signs, blood chemistry, ECG, adverse events (AEs), concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. • Visit 2 (Month 2 (M2) - D60 ± 3): Following items will be recorded: treatment compliance, AEs, concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. • Visit 3 (Month 3 (M3) - D90 ± 3): Following items will be recorded: vital signs, laboratory tests (hematology, blood chemistry, electrolytes, Qmax, urinalysis, 12-lead ECG, total PSA level), concomitant medication, SFQ score, AE assessment, collecting of dispensed IP at the last visit and dispensing of new IP doses. • Visit 4 (Month 4.5 (M4) - D135 ± 3): Following items will be recorded: treatment compliance, vital signs, AEs, concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. Visit 5 (Month 6 (M6)- D180 ± 3): Following items will be recorded: treatment compliance, vital signs, prostate symptom score according to IPSS, laboratory tests (hematology, blood chemistry, electrolytes, Qmax, urinalysis, 12-lead ECG, total PSA level, free-to-total PSA ratio, TRUS; concomitant medication, SFQ score, AE assessment, collecting of the previous dispensed IPs . Follow-up Phone Call (Month 7 (M7)- D210 ± 3): To record any possible AE that may occur after discontinuation of study treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02578953 -
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
|
Phase 1 | |
| Terminated |
NCT02396420 -
Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams
|
Phase 2 | |
| Terminated |
NCT04398966 -
Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia
|
N/A | |
| Not yet recruiting |
NCT06452927 -
EEP in Patients With Urodynamically Proven DU/DA
|
N/A | |
| Completed |
NCT02947958 -
Teleconsultation in Counter-reference Between Tertiary and Primary Care for Patients With Benign Prostatic Hyperplasia
|
N/A | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT00427882 -
Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
|
Phase 4 | |
| Completed |
NCT02244320 -
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
|
N/A | |
| Completed |
NCT01254071 -
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
|
Phase 1 | |
| Recruiting |
NCT04108871 -
Whether Transperineal Prostate Biopsy Under Local-anaesthesia Using a Transperineal-access System is Non-inferior to Standard Transrectal Biopsy to Detect Prostate Cancer in Biopsy-naïve Men
|
N/A | |
| Recruiting |
NCT05686525 -
Clinical Trial on the Effectiveness of TUMT Compared to PAE in Reducing Severe LUTS in Men With BPH
|
N/A | |
| Completed |
NCT01957189 -
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
|
Phase 1 | |
| Completed |
NCT00316732 -
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
|
N/A | |
| Completed |
NCT02715401 -
PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers
|
Phase 1 | |
| Recruiting |
NCT02278679 -
Digital Rectal Exam Proficiency Tool
|
N/A | |
| Completed |
NCT01482676 -
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
|
N/A | |
| Completed |
NCT01376258 -
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
|
N/A | |
| Completed |
NCT00822952 -
Prostate Mechanical Imager (PMI) Clinical Bridging Study
|
N/A | |
| Completed |
NCT00527605 -
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
| Terminated |
NCT00563485 -
Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
|
N/A |